• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice.

作者信息

Celsa Ciro, Cerrito Lucia, Stella Leonardo, Ciccia Roberta, Cabibbo Giuseppe, Ponziani Francesca Romana

机构信息

Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.

Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Palermo, Italy.

出版信息

Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):252-255. doi: 10.21037/hbsn-23-97. Epub 2023 Mar 31.

DOI:10.21037/hbsn-23-97
PMID:37124696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10129882/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a542/10129882/fa50a5ed5388/hbsn-12-02-252-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a542/10129882/fa50a5ed5388/hbsn-12-02-252-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a542/10129882/fa50a5ed5388/hbsn-12-02-252-f1.jpg

相似文献

1
Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice.用于治疗肝细胞癌的免疫疗法：终于应用于临床实践。
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):252-255. doi: 10.21037/hbsn-23-97. Epub 2023 Mar 31.
2
[Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].《中国肝细胞癌免疫检查点抑制剂联合免疫治疗多学科专家共识（2021年版）》
Zhonghua Gan Zang Bing Za Zhi. 2021 Jul 20;29(7):636-647. doi: 10.3760/cma.j.cn501113-20210604-00261.
3
Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?联合治疗能否改善肝癌的免疫检查点阻断反应？
Anticancer Agents Med Chem. 2019;19(2):222-228. doi: 10.2174/1871520618666181114112431.
4
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.免疫检查点抑制剂治疗肝细胞癌与黑色素瘤和非小细胞肺癌相比的安全性。
J Immunother Cancer. 2017 Nov 21;5(1):93. doi: 10.1186/s40425-017-0298-2.
5
Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist.肝细胞癌系统治疗的副作用管理：肝病学家指南。
Clin Liver Dis. 2020 Nov;24(4):755-769. doi: 10.1016/j.cld.2020.07.008. Epub 2020 Sep 2.
6
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.从抗 PD-1 免疫疗法中解耦肝癌反应和不良反应的免疫轨迹。
J Hepatol. 2022 Sep;77(3):683-694. doi: 10.1016/j.jhep.2022.03.039. Epub 2022 Apr 15.
7
[Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].《中国肝细胞癌联合免疫治疗多学科专家共识（2023年版）》
Zhonghua Gan Zang Bing Za Zhi. 2023 Jan 20;31(1):16-34. doi: 10.3760/cma.j.cn501113-20221215-00602.
8
Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.晚期不可切除肝细胞癌的双重免疫检查点抑制剂或联合抗血管生成药物治疗。
Eur J Intern Med. 2023 May;111:37-46. doi: 10.1016/j.ejim.2022.12.025. Epub 2022 Dec 31.
9
[Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions].[免疫检查点抑制剂在肝细胞癌相关不良反应的治疗与管理中的应用]
Zhonghua Gan Zang Bing Za Zhi. 2021 Jun 20;29(6):600-603. doi: 10.3760/cma.j.cn501113-20191010-00368.
10
A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma.一种新型的九lncRNA风险特征与肝细胞癌免疫治疗相关。
Front Oncol. 2021 Sep 15;11:706915. doi: 10.3389/fonc.2021.706915. eCollection 2021.

引用本文的文献

1
Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications.揭示肝癌中的肿瘤内微生物群：当前见解与潜在应用
Clin Mol Hepatol. 2025 Jan 22. doi: 10.3350/cmh.2024.1039.
2
Liver microbiome: an intrahepatic resident playing a role in liver diseases.肝脏微生物群：一种在肝脏疾病中发挥作用的肝内常驻菌群。
Hepatobiliary Surg Nutr. 2024 Aug 1;13(4):686-689. doi: 10.21037/hbsn-24-153. Epub 2024 Jul 4.

本文引用的文献

1
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.
2
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.抗 PD-1 治疗晚期肝细胞癌的分子标志物。
Gastroenterology. 2023 Jan;164(1):72-88.e18. doi: 10.1053/j.gastro.2022.09.005. Epub 2022 Sep 12.
3
Hepatocellular carcinoma and its impact on quality of life: A review of the qualitative literature.
肝细胞癌及其对生活质量的影响：定性文献综述
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13672. doi: 10.1111/ecc.13672. Epub 2022 Aug 16.
4
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.优化晚期肝细胞癌的系统治疗：肝功能的关键作用。
Dig Liver Dis. 2022 Apr;54(4):452-460. doi: 10.1016/j.dld.2022.01.122. Epub 2022 Feb 4.
5
Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.晚期肝细胞癌患者接受PD-1抑制剂治疗后的疗效评估与生存预测：RECIST 1.1、iRECIST和mRECIST标准的比较
Front Oncol. 2021 Dec 9;11:764189. doi: 10.3389/fonc.2021.764189. eCollection 2021.
6
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.2002 - 2033年MAFLD相关肝细胞癌的流行病学趋势与轨迹：ITA.LI.CA数据库
Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21.
7
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.免疫治疗肝细胞癌患者的预后——CRAFITY 评分的建立和验证。
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
8
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.美国癌症免疫治疗学会（SITC）肝癌治疗免疫治疗临床实践指南。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002794.
9
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.无进展生存期早期评估是肝细胞癌免疫治疗试验中总生存期的可靠替代终点。
Cancers (Basel). 2020 Dec 30;13(1):90. doi: 10.3390/cancers13010090.
10
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.